



March 31, 2022

Axcelead Drug Discovery Partners Inc.  
Knowledge Palette, Inc.

## **Axcelead DDP and Knowledge Palette Entered into a Collaborative Research Contract for Establishment of a New Evaluation Platform Using Axcelead DDP's Compound Libraries and Large-Scale Transcriptome Analysis Technologies**

Axcelead Drug Discovery Partners Inc. (headquarters: Fujisawa, Kanagawa; CEO: Yoshinori Ikeura; hereinafter referred to as "Axcelead DDP") and Knowledge Palette, Inc. (headquarters: Kawasaki, Kanagawa; Co-founder, Representative Director: Hiroki Danno, Masakazu Fukuda; hereinafter referred to as "Knowledge Palette") announce that both companies have entered into a collaborative research contract for establishment of a new evaluation platform using Axcelead DDP's compound libraries and Knowledge Palette's large-scale transcriptome analysis technologies.

In this collaboration, whole gene expression data of cells treated with a wide variety of characteristic compounds, which are selected from the Axcelead DDP's compound libraries, will be obtained using Knowledge Palette's large-scale transcriptome analysis technologies. Both companies are aiming to analyze genes linked with various diseases or drug efficacy, safety, toxicity, etc. of the compounds and establish a new evaluation platform which can predict and reveal mechanisms of drug action, by combining the newly obtained data with metadata which Axcelead DDP has stored.

Through the collaborative research, we will build a unique perturbative gene expression database by gene expression profiling of the cells treated with characteristic compounds. By utilizing the database, we can increase the effectiveness of target deconvolution in phenotypic drug screening, drug repositioning, lead generation and optimization, and toxicity prediction.

Yoshinori Ikeura, CEO of Axcelead DDP, says: "The collaborative research with Knowledge Palette allows us to establish a competitively advantageous, unique database from our compound libraries. By using the database, we will make more effective processes for drug discovery research and make a contribution as a hub for drug discovery ecosystem."



Hiroki Danno, Representative Director and CEO of Knowledge Palette, says: " We have an extensive phenotypic drug discovery platform based on whole gene expression profiling. By adding the integrated data from this collaborative research to the database of our platform, we will be able to explore and discover a variety of drug candidates with high success rate of development more effectively. "